Citi Starts MacroGenics (MGNX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Oppenheimer Remains Bullish on Macrogenics (MGNX) Following Announced Entrance into NIAID Contract
September 18, 2015 10:54 AM EDTOppenheimer reiterated an Outperform rating and $48.00 price target on MacroGenics (NASDAQ: MGNX) following the announced entrance into a contract with the National Institute of Allergy and Infectious Diseases (NIAID) for the development of DARTs products for the treatment of HIV. NIAID will pay... More
